CAFC Updates

The Coalition for Affordable Drugs (“CFAD”) filed a petition for inter partes review (“IPR”) challenging the validity of all of the claims of Celgene’s U.S....

Coherus filed an abbreviated Biologic License Application (“aBLA”) seeking FDA approval to market a biosimilar version of Amgen’s pegfilgrastim product Neulasta, a recombinant...

Automotive Body Parts Association (ABPA) sued Ford in district court, seeking a declaratory judgment of invalidity or unenforceability of two design patents that...

In two inter partes review proceedings requested by Samsung, the Patent Trial and Appeal Board upheld all challenged claims of U.S. Patent 8,917,772 , which is...

Indivior markets and holds the New Drug Application (“NDA”) for Suboxone® sublingual film, an opioid addiction treatment that combines buprenorphine and the opioid...

The Patent Trial and Appeal Board found claims of Quake’s Patent and pending Application unpatentable for lack of written description under...

General Electric petitioned the Patent Trial and Appeal Board for inter partes review of U.S. Patent No. 8,511,605 which is assigned to United...

 Elbit brought this action against Hughes alleging that Hughes infringed Elbit’s Patent relating to systems for transmitting information from user terminals to a...

Cellspin sued Fitbit and others for infringing various claims of four different patents relating to connecting a data capture device, e.g., a digital...

UCB owns U.S. Patent Nos. 6,884,434 and 8,232,414, claiming a transdermal therapeutic system comprising rotigotine, a drug used for the treatment...